ClinicalTrials.gov
public full text
Public Domain
Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this Phase III open-label extension study is to evaluate the long-term safety of Tramiprosate (3APS) in patients with mild to moderate Alzheimer's disease.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- 21 U.S.C. § 360ee-1 — FDA rare neurodegenerative disease grant program#577348
- Use of Clinical Notes to Assess Neuropsychiatric Events After Montelukast Initiation#1053178
- Comparative efficacy of neuromodulation techniques for Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trials.#1098106
- Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease#853198
- Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)#890991
Record · ID 830579
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive